Healthcare · rare TRL 4–5 · oncology TRL 8 RUO
With clinicians — not against them.
Endogenius™ helps clinicians make better decisions for each patient — not one protocol for everyone. Three areas: older adults and medicines, rare disease, and cancer. Research use only.
Where we are
Three suites — what they do and where we stand.
Patent-pending tools that rank options and keep a clear trail of why. Not a CE/FDA medical device. Not prescribing advice.
-
Photo: Rhoda Baer / National Cancer Institute (public domain via Wikimedia Commons) Geriatric pharmacology In use · partners nextHelps when an older person takes many drugs and has several health problems — so the plan fits them, not a generic checklist.
Where we are: Built on a large public safety dataset (~244k rows) plus literature. Checks safety for adults, older people, children, and pregnancy. Next step: partner pilots.
-
Photo: Ragesoss / Wikimedia Commons (CC BY-SA 3.0) Rare disease TRL 4–5 · Susac caseHelps when evidence is thin — rare conditions, look-alikes, and sparse data — so clinicians still get a clear, structured view.
Where we are: Lab proof done. Susac syndrome case study passed its checks (including relapse risk and literature tests). Grant path: AKU Society / NAC Liverpool / ERKNet registry plus clinician shadow toward TRL 6. We are still growing the orphan catalog.
-
Photo: National Cancer Institute (public domain via Wikimedia Commons) Precision oncology TRL 8 · two-pagerHelps with cancer decisions: spread vs a new cancer, which treatments to consider, and how drugs may stack on toxicity.
Where we are: Strongest maturity here — independent retrospective checks passed (TRL 8). Short partner brief below. Live clinic trials still need a partner site.
.jpg){kind=link}
Partner pack
Precision oncology two-pager.
Partner research brief (2 pages): metastasis vs independent second cancer, CUP / foresight Whether–Where–When, joint toxicity and cocktail reasoning, and Module M guardrails. Research use only — not a medical device and not a prescription.